IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.031
EU - Europa 3.026
AS - Asia 1.528
SA - Sud America 13
OC - Oceania 7
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 13.616
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.012
CN - Cina 960
IT - Italia 759
SE - Svezia 655
SG - Singapore 452
UA - Ucraina 436
DE - Germania 318
FI - Finlandia 247
RU - Federazione Russa 246
GB - Regno Unito 150
FR - Francia 93
IE - Irlanda 44
IN - India 38
HK - Hong Kong 26
BE - Belgio 22
CZ - Repubblica Ceca 18
CA - Canada 13
NL - Olanda 12
IR - Iran 10
TR - Turchia 8
AU - Australia 6
KR - Corea 6
PL - Polonia 6
EU - Europa 5
BR - Brasile 4
ES - Italia 4
JP - Giappone 4
MX - Messico 4
RO - Romania 4
TW - Taiwan 4
VN - Vietnam 4
AR - Argentina 3
KZ - Kazakistan 3
LT - Lituania 3
MA - Marocco 3
AZ - Azerbaigian 2
CO - Colombia 2
ET - Etiopia 2
ID - Indonesia 2
PH - Filippine 2
TH - Thailandia 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BM - Bermuda 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
EE - Estonia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PE - Perù 1
ZA - Sudafrica 1
Totale 13.616
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.016
Chandler 1.011
Woodbridge 893
Fairfield 825
Ashburn 548
Houston 512
Nyköping 470
Ann Arbor 454
Cambridge 431
Singapore 360
Seattle 321
Wilmington 294
Roxbury 256
Lawrence 241
Nanjing 239
Boardman 171
Des Moines 161
Beijing 146
Bari 132
New York 124
Inglewood 107
Princeton 89
Shenyang 71
Hebei 66
San Diego 55
Rome 53
Dearborn 51
Jiaxing 51
Los Angeles 49
Santa Clara 49
Brooklyn 48
Nanchang 45
Dublin 43
Florence 41
Changsha 40
London 40
Tianjin 37
Paris 34
Guangzhou 30
Milan 25
Pune 25
Redwood City 22
Brussels 21
Helsinki 18
Jinan 17
Noicattaro 16
Washington 16
Kunming 14
Norwalk 13
West Jordan 13
Wuhan 13
Hefei 12
Ningbo 12
Shanghai 12
Augusta 11
Auburn Hills 10
Brno 10
Leawood 10
Ardabil 9
Munich 9
Orta Nova 9
Romola 9
Hong Kong 8
Naples 8
Nuremberg 8
San Mateo 8
Zhengzhou 8
Boydton 7
Chiswick 7
Melito Di Napoli 7
Toronto 7
Fuzhou 6
Kilburn 6
Marseille 6
Omice 6
Yiwu 6
Bengaluru 5
Brescia 5
Genoa 5
Indiana 5
Monmouth Junction 5
Radomsko 5
Torino 5
Trani 5
Triggiano 5
Alcamo 4
Bologna 4
Dong Ket 4
Grafing 4
Grottaglie 4
Modugno 4
Moscow 4
Napoli 4
Noto 4
Taizhou 4
Tappahannock 4
Turin 4
Balıkesir 3
Baotou 3
Bitonto 3
Totale 10.130
Salva come PNG Salva come JPEG
Nome #
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 162
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 113
TRAIL effect on osteoclast formation in physiological and pathological conditions 112
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 107
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 106
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 104
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 103
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 101
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 99
Amyloid in bone marrow smears of patients affected by multiple myeloma 99
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 97
Non-treatment-related chronic myeloid leukemia as a second malignancy 97
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 94
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 94
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 93
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 93
Autoimmune Myelofibrosis: report of three cases and review of the literature 92
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 92
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 91
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 91
Takayasu’s arteritis: a cell mediated large vessel vasculitis 90
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 89
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 85
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 83
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 83
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 83
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 81
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study 79
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 78
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 76
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 75
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide 75
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 75
Ibridizzazione in situ non isotopica. Attualità e prospettive 75
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 75
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 75
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 75
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 74
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 73
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 73
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 73
The Role of LIGHT in Multiple Myeloma-Bone Disease 73
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma 73
A weekly infusion of bortezomib reduces peripheral neuropathy 72
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 71
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 71
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 71
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 70
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 70
Acute tubular necrosis in the hemlock poisoning 68
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 68
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 68
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 68
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 68
Myeloma cells suppress osteoblasts through sclerostin secretion 68
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 68
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 68
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP) 68
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 67
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 66
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 66
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 66
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 66
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 66
Another link between bone and immune system: LIGHT 65
Bendamustine, Bortezomib and Dexamethasone (BVD) in patients with relapsed-refractory multiple myeloma (MM): updated results of a multicenter phase II study. 65
Exploratory survey on multiple myeloma patients' perception 65
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the ‘Rete Ematologica Pugliese E Basilicata’ 65
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 64
Physician-Patient relationship: intervention opportunities for multiple myeloma patients'needs 64
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 64
Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature 63
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia 62
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 62
Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment 61
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 61
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenstrom Macroglobulinemia 60
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 60
Enoxaparin, aspirin, or warfarin for thromboprophilaxis in newly diagnosed myeloma patients receiving thalidomide: a randomized controlled trial 59
Kidney damage by ingestion of ethylene glicol 59
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 59
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience 59
Anti-endothelial cell antibodies in Wegener’s granulomatosis and micropolyarteritis 59
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 59
Microvessel density and angiogenic cytokine expression in autoimmune myelofibrosis compared with chronic idiopathic myelofibrosis 58
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE 58
A phase II study of chlorambucil + rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results 58
Autoimmune bone marrow fibrosis: a distinct clinicopathological entity 57
Rhabdomyolysis and acute tubular necrosis in hemlock poisoning 57
Anticorpi monoclonali anti-idiotipo (Ab2) anti-CD4 inducono anticorpi anti-CD4 in un sistema singenico 57
Economic and social burden of multiple myeloma in Italy – Co.Mi.M. Study 57
The role of molecular genetics in the diagnosis of lymphoma 56
Anti-endothelial cell autoantibodies in Takayasu’s arteritis 56
Thalidomide, dexamethasone, doxil and velcade (ThaDD-V) induction therapy followed by consolidation-maintenance is very effective in early relapsed/refractory MM 56
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 56
Bone marrow angiogenesis in autoimmune myelofibrosis 56
Failure of an in vitro model of osteoclastogenesis in human plasma cell leukaemia (PCL) 56
Anemia emolitica autoimmune sviluppata durante il trattamento di epatite cronica C con interferone-alfa 55
Antigene CD4 solubile nei preparati di immunoglobuline umane per vie endovenosa 55
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 55
Totale 7.403
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.157
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.157
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.440 0 0 0 0 0 151 325 174 314 131 302 43
2020/20211.949 197 63 167 68 306 101 234 126 204 242 151 90
2021/20221.790 78 253 7 128 56 77 73 96 126 79 314 503
2022/20232.648 380 231 111 271 344 375 41 300 495 16 45 39
2023/20241.332 200 212 73 66 97 238 65 69 8 55 101 148
2024/20251.178 114 55 403 140 110 356 0 0 0 0 0 0
Totale 13.933